ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote Security Holders. |
On June7, 2017, Ardelyx, Inc. (the Company) held its Annual
Meeting of Stockholders (the Annual Meeting) at the Companys
principal executive offices located at 34175 Ardenwood Blvd.,
Suite 200 (2nd Floor),
Fremont, California 94555. Only stockholders of record at the
close of business on April12, 2017, the record date for the
Annual Meeting, were entitled to vote at the Annual Meeting. As
of the record date, 47,386,756 shares of the Companys common
stock were outstanding and entitled to vote at the Annual
Meeting. At the Annual Meeting, 37,974,033 shares of the Companys
common stock were voted in person or by proxy for the two
proposals set forth below, each of which is described in the
Companys Definitive Proxy Statement on Schedule 14A filed with
the U.S. Securities and Exchange Commission on April25, 2017.
Proposal No.1 Election of Directors
The Companys stockholders elected the ClassIII director nominees
below to the Companys Board of Directors (the Board) to hold
office until the 2020 Annual Meeting of Stockholders or until
their successors are elected.
| ClassIII Director Nominees | Votes For | VotesWithheld | BrokerNon-Votes | |||||||||
|
Robert Bazemore |
31,407,887 | 3,952,069 | 2,614,077 | |||||||||
|
Gordon Ringold, Ph.D. |
30,017,324 | 5,342,632 | 2,614,077 | |||||||||
|
Richard Rodgers |
31,413,977 | 3,945,979 | 2,614,077 |
Proposal No.2 – Ratification of Selection of
Independent Registered Accounting Firm
The Companys stockholders ratified the selection, by the Audit
Committee of the Board, of Ernst Young LLP as the independent
registered public accounting firm of the Company for the fiscal
year ending December31, 2017.
| Votes For | VotesAgainst | Abstentions | BrokerNon-Votes | |||
| 37,963,172 | 10,661 |
About ARDELYX, INC. (NASDAQ:ARDX)
Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia. RDX022 is its oral, non-absorbed potassium-binder. Its development programs also include RDX009 Program, RDX013 Program and RDX011 Program.
